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Introduction: Resistance to anti-estrogen therapies is a major cause of disease relapse and mortality in estrogen
receptor alpha (ERα)-positive breast cancers. Tamoxifen or estrogen withdrawal increases the dependence of breast
cancer cells on Notch signalling. Here, we investigated the contribution of Nicastrin and Notch signalling in
endocrine-resistant breast cancer cells.
Methods: We used two models of endocrine therapies resistant (ETR) breast cancer: tamoxifen-resistant (TamR)
and long-term estrogen-deprived (LTED) MCF7 cells. We evaluated the migratory and invasive capacity of these
cells by Transwell assays. Expression of epithelial to mesenchymal transition (EMT) regulators as well as Notch
receptors and targets were evaluated by real-time PCR and western blot analysis. Moreover, we tested in vitro
anti-Nicastrin monoclonal antibodies (mAbs) and gamma secretase inhibitors (GSIs) as potential EMT reversal
therapeutic agents. Finally, we generated stable Nicastrin overexpessing MCF7 cells and evaluated their EMT
features and response to tamoxifen.
Results: We found that ETR cells acquired an epithelial to mesenchymal transition (EMT) phenotype and displayed
increased levels of Nicastrin and Notch targets. Interestingly, we detected higher level of Notch4 but lower levels of
Notch1 and Notch2 suggesting a switch to signalling through different Notch receptors after acquisition of resistance.
Anti-Nicastrin monoclonal antibodies and the GSI PF03084014 were effective in blocking the Nicastrin/Notch4 axis
and partially inhibiting the EMT process. As a result of this, cell migration and invasion were attenuated and the
stem cell-like population was significantly reduced. Genetic silencing of Nicastrin and Notch4 led to equivalent
effects. Finally, stable overexpression of Nicastrin was sufficient to make MCF7 unresponsive to tamoxifen by
Notch4 activation.
Conclusions: ETR cells express high levels of Nicastrin and Notch4, whose activation ultimately drives invasive
behaviour. Anti-Nicastrin mAbs and GSI PF03084014 attenuate expression of EMT molecules reducing cellular
invasiveness. Nicastrin overexpression per se induces tamoxifen resistance linked to acquisition of EMT phenotype.
Our finding suggest that targeting Nicastrin and/or Notch4 warrants further clinical evaluation as valid therapeutic
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Resistance to endocrine therapies remains a major
challenge in the treatment of estrogen receptor alpha-
positive (ERα + ve) breast cancers. Despite an initial
responsive phase, many patients will have recurrent
endocrine-resistant disease associated with reduced
survival [1,2]. Endocrine-resistant tumours frequently
display an aggressive phenotype with enhanced metastatic
capacity, features that more often typify ERα-negative
(ERα-ve) tumours [3]. Consistent with clinical outcomes,
quantitative proteomic analysis of acquired tamoxifen
resistance cells confirmed signatures associated with an
increased migratory capacity [4]. Several studies dem-
onstrated that acquired resistance to drugs that block
ER signalling is the consequence of activation of alter-
native survival signalling via growth factor receptors,
such as epidermal growth factor receptor (EGFR) and
human epidermal growth factor 2 (HER2), that enable
ERα + ve breast cancer cells to escape anti-estrogen ac-
tions and contribute to an invasive phenotype [5,6].
Recently, the contribution of Notch pathway in endo-
crine therapy resistance has been revealed by several
studies [7-9]. In particular, it has been demonstrated that
Notch signalling is augmented in endocrine therapies re-
sistant (ETR) cells following a global reprogramming of
the epigenome. The growth of resistant breast cancer
cells can be abrogated by blocking Notch signalling,
which is activated in these cells [7]. Moreover, it has
previously been shown, in this system, that estradiol in-
hibits Notch activity by altering Notch receptor cellular
localization. Tamoxifen or estrogen withdrawal block
this effect and increase the dependence of breast cancer
cells on Notch signalling [10]. Hao et al., have also dem-
onstrated that Notch activates the transcription of ERα
target genes via a nuclear IKKα-dependent pathway [11].
Pharmacological inhibition of Notch activation with
gamma-secretase inhibitors (GSIs) in combination with
tamoxifen has synergistic effects in ERα + ve breast cancer
in vivo models [10,11]. Recently, a functional crosstalk be-
tween PKCα and Notch4 has been reported in endocrine-
resistant breast cancer cells [9].
The Notch signalling pathway is a key regulator of epi-
thelial to mesenchymal transition (EMT) affecting migra-
tion and invasion of breast cancer cells [12], and several
studies link EMT to the generation of cancer stem cells
(CSCs) with mesenchymal and self-renewal features neces-
sary for dissemination and formation of metastasis [13,14].
The Notch signalling pathway has also been implicated
in controlling the fate of putative stem cells in the nor-
mal human mammary gland [15,16] and in the regulation
of CD44+CD24- breast CSCs in both ductal carcinoma in
situ (DCIS) and invasive carcinoma [17-19]. Specifically,
it has been found that breast CSCs activity depends on
Notch4 receptor signalling and its inhibition cansignificantly reduce mammosphere formation in pri-
mary human DCIS in vitro as well as tumour formation
in vivo [8].
Importantly, we recently highlighted the importance of
Nicastrin, a component of the gamma secretase (GS) en-
zyme, for the expansion of breast CSC population and
their invasive features [13]. Nicastrin is highly expressed
in breast cancers and confers worse overall survival in
ERα-ve tumours [20]. It has also been demonstrated that
Nicastrin stable knockdown induces Notch inhibition in
basal-like breast cancer cells, sensitising them to anti-
proliferative effects of EGFR inhibition [21]. Structur-
ally, Nicastrin is the only GS component with a large
extracellular domain that makes this protein a potential
target for monoclonal antibody (mAb) therapy. In a re-
cent study, Hayashi et al. reported the neutralization of
the GS activity by a novel mAb against the extracellular
domain of Nicastrin. This antibody abolished the GS
activity-dependent growth of cancer cells in a xenograft
model [22].
We developed and fully characterized two mAbs against
the extracellular domain of Nicastrin that reduce tumour
and metastasis formation in vivo of triple-negative breast
cancer cell lines ([20] and submitted data).
Here, we show the contribution of Notch4 and Nicastrin
in the development of endocrine therapies resistance. We
present data supporting the efficacy of GSI PF03084014
and anti-Nicastrin mAbs that can reverse and potentially
re-sensitize endocrine-resistant breast cancers.
Methods
Cell lines, antibodies, mAbs and GSI
MCF7 and tamoxifen-resistant (TAM-R) cells derived
from MCF7 as previously described [3] were a kind gift
from Dr. Hiscox (Welsh School of Pharmacy, Cardiff Uni-
versity, Wales, UK). Long-term estrogen-deprived cells
(LTED) were derived from MCF7 after six-month estro-
gen deprivation as previously described and were a kind
gift from Dr. Hellis. MCF7 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 10% fetal calf serum (FCS). TAM-R and LTED were
maintained in phenol-red free DMEM containing 10%
charcoal stripped fetal calf serum (SFCS). Both media were
supplemented with 2 mM L-glutamine, 100 units/mL
penicillin, 0.1 mg/mL. 10−7 M 4-OH-tamoxifen was added
routinely to TAM-R. A mycoplasma test was carried
out monthly; cells were used for a limited number of
passages. All antibodies were bought from Cell Signal-
ing (Merck KGaA, Darmstadt, Germany) (Notch1 D1E11
3608S, Notch2 5732P, Notch3 5276P, Rac1 2465P, Cdc42
2466P, IQGAP1) with the exception of Notch4, SC-5594,
(Santa Cruz Biotechnology, Dallas, Texas, USA) Actin
Ab6276, (Abcam, Cambridge, UK) Nicastrin and αTubulin
(N1660, clone B512, Sigma-Aldrich, St. Louis, MI, USA)
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USA) (PF03084014) and Roche (Basel, Switzerland)
(RO4929097) and used at 10 μM final concentration.
Tamoxifen was purchased from Sigma-Aldrich (H7904).
For the generation of Nicastrin stably overexpressing
MCF7 cell line, the cDNA encoding full-length human
Nicastrin was subcloned into a retroviral expression
vector pMXs-puro and the construct was kindly provided
by Prof. Gopal Thinakaran, (University of Chicago, USA).
The pMXs-puro-nicastrin retroviral vector was used to
infect MCF7 cells. Control cells were generated by
retroviral transduction of the empty vector pMXs-puro
(Cambridge Bioscience, Cambridge, UK). Stable, poly-
clonal cell populations were established after puro-
mycin selection (0.5 μg/ml).
Anti-nicastrin monoclonal antibodies
mAbs against Nicastrin extracellular domain were pro-
duced by genetic immunization of rats using DNA frag-
ment corresponding to Nicastrin amino acids 34-669 aa
(Genovac, Freiburg, Germany). Antibody clones mAb1
and mAb2 were purified and used in subsequent experi-
ments. Rat immunoglobulin G (IgG) (Ab36371) was used
as control. In all experiments where antibodies were used,
cells were pre-treated with 50 μM (mAbs or control) for
30 minutes at room temperature on a tube rotator before
seeding.
FACS analysis using fluorescein isothiocyanate
(FITC)-conjugated antibodies
TAM-R cells were cultured to 70 to 80% confluence and
detached from the cell culture flasks using EDTA. Cell
pellets were obtained and washed with cold phosphate-
buffered saline (PBS) containing 0.1% BSA and 0.02%
sodium-azide (NaN3). All further steps were performed
on ice and all centrifugation steps at 4°C. Anti-Nicastrin
antibodies were added and incubated on an orbital
shaker at 4°C for 1 hour. Cells were washed three times
in cold PBS + BSA +NaN3. The secondary, species-
specific anti-rabbit (rat) IgG-FITC-conjugated Abs was
added at 1:200 dilution for 1 hour, and incubated on the
orbital shaker in the dark. Cells were washed twice in
PBS + BSA +NaN3 and finally resuspended in 400 μl of
PBS. Immunofluorescent staining acquisition and analysis
of 10,000 gated, live cells was done using FACSCanto II
(Becton-Dickinson, Erembodegem, Belgium) and FlowJo
software, Version 7.1 (Tree Star, Inc., Ashland, OR, USA).
siRNA
Small interfering RNA (siRNA) against Nicastrin were
previously described (Lombardo et al.). siRNA against
Notch4 (Gene Solution siRNA gene ID4855: Hs-Notch4-
1 S100065170, Hs-Notch4-3 S100065184, Hs-Notch4-
5 S102633533, Hs-Notch4-6 S102633540) were purchasedfrom Qiagen (Hilden, Germany) and pooled together.
Silencer green fluorescent protein (GFP) from Ambion
(Invitrogen, Carlsbad, CA, USA) (AM4626) was used as
negative control. Both mRNA and protein levels were
tested to ensure knockdown efficacy. TAM-R cells were
seeded at 1.5 × 105 cells per well in 6-well plates and
transfected the following day with 50 nM siRNA using
Hyperfect transfection reagent (Qiagen 301705). For
Nicastrin knockdown, cells were analysed 72 hrs later.
For Notch4 knockdown, cells were harvested after
72 hrs and 2 × 105 cells were reseeded. Cells were trans-
fected on the same day with 50 nM siRNA. The samples
were analysed 72 hrs later (total knockdown 144 hrs).
RNA extraction and real-time PCR
Total RNA was extracted using RNeasy columns (Qiagen),
and cDNA was reverse transcribed from 2 μg RNA using
Applied Biosystems technology (Invitrogen) (AB 4368814).
Quantitative real-time RT-PCR (qRT-PCR) was per-
formed in triplicate using SYBR Green mix (Invitrogen
4309155) on SDS7900HT FAST detection system (Ap-
plied Biosystems). For the primer sequence refer to
Table S1 in Additional file 1. Samples underwent three-
step amplification at 94°C (1 min), 60°C (30 sec), 72°C
(30 sec). Melting curves were analysed after 40 cycles.
The Ct values for test genes were normalized to ACTB
and relative expression represented as 2−ΔΔCt. To meas-
ure microRNA (miRNA) 200c expression levels, total
RNA extracted was used to perform RT-qPCR using
Taqman mature miRNA primers and probes (Applied
Biosystems). Briefly, mature miRNA expression was mea-
sured using stem-loop reverse transcriptase primers for
miRNA cDNA synthesis followed by Taqman PCR ana-
lysis. RNA was reverse transcribed followed by qPCR on a
7900 HT Fast Real-Time PCR System (Applied Biosys-
tems). Duplicate samples and an endogenous control
(small nuclear RNA (snRNA) U6) were used throughout.
Expression levels of each miRNA were evaluated using
comparative threshold cycle (Ct) method using the 2−ΔΔCt
method with normalization to U6.
Cell lysis and western blot
Briefly, cells were washed twice in ice-cold PBS and lysed
in RIPA (Sigma-Aldrich R02780) buffer supplemented
with Protease (Roche 11697498001) and phosphatase in-
hibitors (Sigma-Aldrich 93482) for 10 minutes in ice with
intermittent vortexing. Samples were cold-centrifuged at
maximum speed for 15 minutes and supernatant trans-
ferred to a clean cold eppendorf. The protein concentra-
tion of each sample was determined using a bicinchoninic
acid (BCA) assay (Thermo Fisher Scientific, Waltham,
MA, USA, 23227). Equal amounts of lysates were subject
to immunoblotting on SDS-PAGE. Proteins were trans-
ferred to a Biotrace NT membrane (VWR, Radnor, PA,
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Proteins were visualized using donkey anti-mouse, and
anti-rabbit secondary antibodies conjugated to the IRDyes,
IR680-LT (926-68022) or IR800 (926-32213) (LI-COR Bio-
sciences, Lincoln, NE, United States) and the LI-COR
Odyssey 2.1 system. 16-bit images were analysed and
quantified using the Odyssey analysis software.
Sulforhodamine B colorimetric, and Transwell assay
Sulforhodamine B (SRB, Sigma-Aldrich S9012) colorimet-
ric assay was used to assess cell proliferation and has been
previously described (Lombardo et al.). For drug resist-
ance experiments, cells were seeded at 3,000 per well in a
96-well plate and allowed to adhere overnight. Time 0
plate was fixed at this time, further plates were treated
with 10−7 M 4-hydroxy-tamoxifen (4-OH-tamoxifen) and
assayed at two-day intervals. For knockdown experiments,
cells were seeded as in knockdown experiments, after
72 hours cells were harvested and subject to SRB protocol
just described.
Transwell (VWR, 3422) cell invasion assay was used to
assess cell invasive/migratory capacity. 2 × 105 cells were
pre-treated as previously described and seeded on a 6-
well plate. Fifty-four hours later, cells were harvested
and counted. A total of 50,000 cells were washed and re-
suspended in 200 μl αMEM and seeded in duplicate on
the matrigel-coated (Becton Dickinson, Franklin Lakes,
NJ, USA, 356237) Transwell upper chamber to assess in-
vasion. To determine migration capacity, matrigel was
excluded. FCS DMEM or DCFCS DMEM was used as
chemoattractant for MCF7 and TAM-R respectively.
Eighteen hours later, cells that did not migrate were
wiped off from the top chamber with a cotton swab, the
bottom chamber was fixed with 4% PFA (VWR P38),
washed twice in PBS, cut and mounted on coverslips
coated with Mowiol (Applichem, Darmstadt, Germany,
A9011) infused with DAPI (Lonza, Basel, Switzerland, PA-
3013). Ten pictures per condition were taken using an
EVOS microscope system (Advanced Microscopy Group,
Bothell, WA, USA). Fifty different fields were counted.
Crystal violet staining
The cells were seeded on a 6-well plate and the pictures
were taken at 50% confluence. Cells were washed twice in
1X PBS. 1 ml of Crystal Violet (100 mg Crystal Violet,
Sigma-Aldrich, 20 mls ethanol, 80 mls dd-H2O) was added
to the well for 30 minutes. Cells were washed 5X in PBS
and pictures were taken using Axiovert system microscope
(Carl Zeiss, Oberkochen, Germany).
CD24/CD44 sorting
FACS sorting experiment was previously described
(Lombardo et al.). Cells were pre-treated and seeded in
6-well plates for 72 hrs.Mammosphere formation assay and fractionation
Following MAbs/GSI pre-treatment, TAM-R cells were
plated at single cell suspension at a density of 1,000
viable cell/well in ultralow attachment 24-well plates
(Corning Life Sciences, Tewksbury, MA, USA). Cells
were grown in a serum-free mammary epithelial growth
medium (MEBM) (Lonza) supplemented with B27 (Invi-
trogen), 20 ng/ml EGF, 20 ng/ml bFGf (BD Biosci-
ences, San Jose, CA, USA), and 4 μg/ml heparin
(Sigma-Aldrich). Mammospheres were grown for 10 days
and phase contrast images were taken using Axiovert
system microscope (Carl Zeiss). For the second gener-
ation experiment, first generation mammospheres were
collected and spun at 500 × g per 5 minutes. The pellet
was resuspended in 50 μl Trypsin and the sample was
passed 25 times through a sterile needle to get single
cell suspension The same density of cells as in first gen-
eration culture was seeded, and cells were allowed to
grow for 10 days.
Cytoplasm, membrane, and nucleus were fractioned
using Subcellular Protein Fractionation kit from Thermo
Fisher Scientific (78840) according to the manufacturer
protocol. Adherent and mammospheres MCF7 and TAM-
R were lysed in parallel. 10 μg of each fraction were loaded
onto SDS-PAGE gel.
Immunofluorescence
Cells were fixed in pre-warmed 4% paraformaldehyde/
PBS and permeabilized in 0.2% Triton-X-100/PBS for
10 minutes. Cells were stained with anti-E-cadherin anti-
body (HECD-1) (M106, Takara Bio Inc., Shiga, Japan)
and visualised with Alexa Fluor 488. Nuclei were counter-
stained with DAPI (Lonza, PA-3013). Images were taken
using Axiovert system microscope (Carl Zeiss).
Statistical analysis
Two-tailed Student t test was employed to determine
the statistical significance of the differences observed. A
P value below 0.05 was considered significant.
Results
ETR breast cancer cells display migratory behaviour, high
levels of EMT-related genes, Nicastrin and Notch4
In our study, we used two alternative models of acquired
ETR: 1) tamoxifen-resistant (TAM-R) cells obtained from
MCF7 cells cultured with 4-OH-TAM over a period of
12 months as previously described [3]; 2) MCF7 LTED
cells, which gradually acquired estrogen independence
upon culture in estrogen/steroid-free conditions model-
ling aromatase inhibitor resistance [7].
We first demonstrated that ETR cells were able to
proliferate in estrogen-deprived medium and in pres-
ence of 4-OH-TAM as opposed to the parental MCF7
cells that showed growth arrest in the same conditions
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S2A in Additional file 3). Furthermore, we observed
that although MCF7 cells grew in clusters and showed
a typical epithelial cobblestone appearance, ETR cells
displayed elongated, irregular morphology (Figure 1B,
Figure S1B in Additional file 2). These changes in morph-
ology suggested that ETR cells have undergone the EMT
process that led to the acquisition of invasive and migra-
tory capacity (Figure 1C, Figure S1C in Additional file 2).
We further confirmed that these cells displayed reduced
mRNA levels of E-cadherin, a cell-cell adhesion protein
usually lost during EMT process, and increased levels
of important EMT-related genes such as Vimentin,
CD44, IQGAP1, RAC1, CDC42, SNAIL, TWIST, ZEB2
and mir200c (Figures 1D and Figure S1D in Additional
file 2). We confirmed by western blot analysis that ZEB2
and B-catenin were upregulated. E-cadherin total expres-
sion levels were not significantly reduced. However, we ob-
served a reduction of E-cadherin expression at cell-cell
contact in the resistant cells (Figure 1F). To determine
whether the Notch pathway is involved in ETR invasive fea-
tures, we first assessed the levels of Notch receptors, Notch
targets and Nicastrin, previously described as an important
regulator of EMTand breast cancer stem cells [13].
Western blot and qRT-PCR showed that ETR cells dis-
played increased levels of Nicastrin and Notch targets
(Hes1, Hey1 and Hes5). Interestingly, we also found
lower mRNAs levels of Notch1, Notch2 and higher
levels of Notch4 (Figure 1G). By western blot analysis
we evaluated the expression of Notch intracellular do-
main (ICD) (Figure 1H). Notch activation was confirmed
by EDTA treatments (Figure S2b in Additional file 3).
We found that ETR cells displayed lower levers of
Notch1 and Notch2 intracellular domains (N1ICD and
N2ICD). By contrast, ETR cells displayed an increase ac-
tivation of Notch4 (N4ICD), suggesting a strong signal-
ling through this receptor (Figures 1G-H, Figure S1E-F
in Additional file 2).
Targeting NCT/Notch4 signalling induces reversal of EMT
in ETR cells
To investigate the role of Nicastrin and Notch4 in ETR
cells, which showed EMT features, we examined the
effects on cell invasion or migration of two anti-
Nicastrin mAbs (mAb1 and mAb2) that specifically
bind Nicastrin at the cell surface of TAM-R cells com-
pared to MCF7 cells (Figure 2A) and thereby block
Notch signalling. We compared these results with two
different GSIs (PF03084014, and RO4929097). Invasion
and migration were significantly inhibited by mAb1,
and so all the EMT genes. mAb2 was less effective in
inhibiting migration and invasion behaviour but still ef-
fective in reducing EMT markers. Lastly, GSIPF was as
potent as mAb1 in affecting migration and invasionand most of the EMT genes (Figure 2B-C, Figure S3A-B
in Additional file 4). However, RO4929097 (GSIRO) did
not show a significant effect (Figure S3A-D in Additional
file 4 and Figure S3F in Additional file 4). E-cadherin
mRNA expression levels significantly increased after
mAb1 and mAb2. Importantly, all the treatments par-
tially induced E-cadherin re-localisation to the cell-cell
contact in TAM-R cells. (Figure S4A in Additional file 5)
Upon mAb1, mAb2 treatments we observed a reduction
of Hes1, Hey1, and Hes5, while GSIPF treatment was
able to reduce Hey1mRNA expression levels (Figure 2D,
Figure S3E in Additional file 4). Concomitantly, efficacy
was further confirmed by reduction of Notch2, Notch3
and Notch4 activation (Figure 2E, Figure S3E in Additional
file 4). Interestingly, we observed decreased levels of
Nicastrin (Figures 2E). GSIRO efficiently attenuated the
cleavage of Notch1, Notch2, Notch3, and Notch targets
expression. However, it increased Notch4 and Nicastrin
expression (Figures S3F in Additional file 4). To further
validate the role of Nicastrin and Notch4 in mediating
ETR cells behaviour, we depleted Nicastrin and Notch4
using specific siRNAs in TAM-R cells. siRNA Notch4
deconvolution is shown in Figure S2C in Additional file
3. We pooled the oligos together for further analyses.
Nicastrin siRNAs were used as previously described
[13,20]. siRNA against Notch4 were effective in redu-
cing the expression of different Notch targets (Hes1,
Hey1, Hes5) as well as EMT genes (Figure 3A and C).
siRNA against Nicastrin efficiently reduced Hes1, Hes5
and most of the EMT genes (Figure 3A-D). Moreover, we
confirmed a partial E-cadherin re-localisation to the cell-
cell contacts in TAM-R cells upon siRNA (Figure 3B).
These data clearly suggest that the downregulation of
Nicastrin and Notch4 expression in ETR cells could re-
verse the EMT phenotype.
Surprisingly, following Notch4 depletion we observed
a reduction of Nicastrin both at protein and mRNA
levels (Figure 3A-C). As expected, Nicastrin knockdown
decreased Notch4 cleavage as a consequence of GS ac-
tivity inhibition (Figure 3D), suggesting a positive feed-
back mechanism between Notch4 and Nicastrin.
Nicastrin and Notch4 regulates stem cell content and
properties in ETR cells
We next examined whether the altered expression of
EMT-related genes in TAM-R cells correlated with
changes in CD44 and CD24 expression, reflecting an effect
on the stem cell population. TAM-R cells showed a higher
content of stem-like cells defined by the CD44+/CD24−
phenotype compared to MCF7 cells (Figure 4A). Con-
sistent with this, the mammosphere formation assay
showed that TAM-R formed more primary and second-
ary mammospheres than parental MCF7 cells (Figure 4B).
We found that the percentage of CD44+/CD24− cells
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Figure 2 Nicastrin (NCST) monoclonal antibodies (mAbs) and gamma secretase inhibitor (GSI) Pfizer can reverse epithelial to mesenchymal
transition (EMT) process. (A) Binding of anti-NCST mAbs to endogenous cells surface Nicastrin of tamoxifen-resistant (TAM-R) and MCF7 cells. Non-
permeabilised cells were incubated with 50 μg/ml of mAbs1/2, followed by incubation with the secondary anti-rat FITC antibody. Rat immunoglobulin
G (IgG) was used as control. Binding was assessed by FACS. (B) TAM-R cells were pre-incubated for 30 minutes with 50 μg/ml of mAb1/2, or 10 μM
GSIPF (PF03084014). For invasion assay, cells were seeded in the upper compartment on top of matrigel-coated membrane and allowed to
invade for 72 hrs. For motility assay, matrigel was excluded. Pre-treated cells were seeded on 6-well plates for 54 hrs, then harvested and
counted. A total of 50,000 were transferred to the upper compartment for 18 hrs. The results are representative of three biological and two
technical replicates. (C, D) qRT-PCR showing mAbs and GSIPF treatment modulate EMT and Notch-responsive genes. Cells were treated as in
B and analysed 72 hrs later. microRNA (mRNA) levels are represented as fold induction normalised to GAPDH and compared to control. Results
represent three biological as well as three technical replicates of each. (E) Representative western blot showing downregulation of Nicastrin
and Notch proteins following mAbs and GSIPF treatments. IQGAP1 was chosen as EMT representative protein. Quantitation represents the
average from three biological experiments (bars represent standard deviation (SD)).
(See figure on previous page.)
Figure 1 Tamoxifen-resistant cells (TAM-R) are resistant to tamoxifen (4-OH-TAM), phenotypically distinct, more invasive and migratory
compared to wild-type MCF7. (A) MCF7 and TAM-R cells treated with vehicle (EtOH) or 10−7 M 4-OH-TAM were plated (3 × 103/well) in 96-well
plates and allowed to adhere. One plate was fixed and annotated as Day 0. A sulforhodamine B (SRB) assay was performed every two days until Day 6.
The experiment was repeated three times and each time six technical replicates were used. (B) Cells were stained with Crystal Violet and 10X images
were taken with a bright-field microscope when cells were 50% confluent (bar represents 400 μm). (C) Boyden chamber-based assay was used to
determine the cells invasive or migratory capacity. Cells were allowed to invade or migrate for 72 or 18 hrs respectively before the insert was
fixed, cut, and mounted in Mowiol infused with DAPI. 4X images were taken with a fluorescent microscope (bar represents 1,000 μm). The results
are representative of three biological and two technical replicates. (D) Quantification of microRNA (mRNA) levels of epithelial to mesenchymal
transition (EMT) markers or Notch genes (G) analysed by qRT-PCR. Fold change is shown in TAM-R compared to MCF7 cells, normalised to GAPDH. Results
represent three biological as well as three technical replicates of each. (Bars represent standard deviation (SD) *P <0.05 **P <0.01, ***P <0.0001, t Student,
two-tails). (E) Western blot validation for representative EMT markers and Notch proteins (H). ActinB was used as loading control. (F) Representative
images showing E-cadherin expression in MCF7 and TAM-R cells at cell-cell contact.
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Figure 3 Notch4 and Nicastrin knockdown reduce epithelial to mesenchymal transition (EMT) genes expression. (A) qRT-PCR showing
Notch4 and Nicastrin knockdown effect on EMT as well as Notch-responsive genes. microRNA (mRNA) levels are normalised to GAPDH. (n = 3 bars
represent standard deviation (SD) *P <0.05.) (B) Representative images showing E-cadherin expression in MCF7 after control, Notch4 or Nicastrin
knockdown. (C) Representative western blot confirming specificity for small interfering RNA (siRNA) targeting Notch4. IQGAP1 was chosen as EMT
representative protein (n = 3, bars represent SD *P <0.05). (D) Representative western blot confirming Nicastrin siRNA effect on Notch receptors
and IQGAP1 (n = 3, bars represent SD *P <0.05).
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treatments (Figure 4A). Importantly, all the treatments re-
duced the sphere-forming efficiency (SFE) at the first gen-
eration, both mAb1 and GSIPF affected the self-renewal
as demonstrated by the reduced SFE at the second gener-
ation of mammospheres (Figure 4C). Finally, MCF7 and
TAM-R derived mammospheres were fractionated into
cytoplasm, membrane and nucleoplasm. We found that,
TAM-R-derived mammospheres expressed higher levels
of Nicastrin in the membrane fraction, whereas Notch4
was increased in both membrane and nuclear fractions
(Figure 4D), implying a role of these two proteins in the
putative ETR stem cell population.
Overexpression of Nicastrin confers tamoxifen resistance
through Notch4 activation
To further investigate the contribution of Nicastrin in
ETR cells, we stably overexpressed Nicastrin in MCF7
cells (MCF7 NCST). Nicastrin overexpression was con-
firmed at the protein and mRNA levels (Figure 5A-B).
Nicastrin overexpression induced activation of Notch1,
Notch3 and Notch4 (Figure 5A). Moreover, Notch targetslevels (Hes1, Hey1 and Hey5) were increased (Figure 5B).
We also observed a significant increase in EMT genes
(Vimentin, CD44, IQGAP1, and CDC42) consistent with
the morphological alteration and migration behaviour
of Nicastrin overexpressing cells (Figure 5A,C-E). E-
cadherin mRNA levels did not significantly change in
NCST overexpressing cells. However, by immunofluor-
escence, we observed a reduction of E-cadherin expres-
sion at cell-cell contact in the these cells (Figure 5D).
Finally, since ETR cells displayed high levels of
Nicastrin, we evaluated whether Nicastrin can induce
tamoxifen resistance. As shown in Figure 6A, Nicastrin
overexpression was able to make MCF7 cells unre-
sponsive to 4-OH-TAM. Importantly, ERα protein
levels did not change in MCF7 NCST cells (Figure 6B).
In addition, ERα target genes (TTF1, PGR, GREB1 and
CTPSD) were efficiently reduced by 4-OH-TAM treat-
ment in both control and NCST cells (Figure 6C).
These data suggest that Nicastrin leads to an EMT
phenotype through the activation of the Notch path-
way and this can enable cancer cells to escape anti-
estrogen treatments.
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Figure 4 Stem cell content population is increased in tamoxifen-resistant (TAM-R) cells and is affected by anti-Nicastrin (NCST) monoclonal
antibodies (mAbs) and gamma secretase inhibitor (GSI) treatment. (A) Percentage of CD44+/CD24− cells assessed by FACS in TAM-R compared
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and MCF7 NCST cells treated with vehicle (EtOH) or 10−7 M 4-OH-TAM were plated (3 × 103/well) in 96-well plates and allowed to adhere. One
plate was fixed and annotated as Day 0. A sulforhodamine B (SRB) assay was performed every two days until Day 6. The experiment was repeated
three times and each time six technical replicates were used. (B) Representative western blot of estrogen receptor alpha (ERα) protein levels in
MCF7 CT and MCF7 NCST cells. ActinB was used as loading control. (C) Quantification of microRNA (mRNA) levels of ERα target genes analysed
by qRT-PCR. Fold change is shown in MCF7 NCST compared to MCF7 CT cells, normalised to GAPDH. Results represent three biological as well as
three technical replicates of each. (D) Representative western blot confirming Notch4 small interfering RNA (siRNA) in MCF7 NCST cells and the
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MCF7 NCST cells, we observed downregulation of
Nicastrin confirming the existence of a positive feedback
between these two proteins (Figure 6D). Last, 4-OH-
TAM response was restored in MCF7 NCST cells after
Notch4 siRNA (Figure 6E). These results suggest a direct
role of Notch4 in endocrine resistance due to Nicastrin.
Moreover, expression data from publically available breast
cancer patient dataset demonstrate that Notch4 expres-
sion significantly correlates with several markers of EMT
transition. Indeed, Pearson correlation coefficient between
RNA-seq data shows that high expression of Notch4
correlate with high expression of VIM, ZEB1/2 and
SNAI1/2/3 while correlating with low expression of E-
cadherin (CHD1) (Figure S5A in Additional file 6). Finally,
we found a positive correlation between Notch4 expres-
sion and post-progression survival in ERα-positive breast
cancer patients (Figure S5B in Additional file 6).
Discussion
Endocrine therapies have been used for the treatment of
ERα+ve breast cancers for over 30 years [23]; nonethe-
less the precise mechanisms behind the development of
resistance are currently unknown.
In this study we demonstrate the key contributions of
Notch4 and Nicastrin in the development of resistance
to endocrine therapies. We used two different models of
endocrine resistance: tamoxifen-resistant cells, obtained
after culturing MCF7 cells with 4-hydroxy tamoxifen
over a period of 12 months [3], and long-term estrogen-
deprived cells, which have gradually acquired resistance
after culture in estrogen/steroid-free conditions, model-
ling aromatase inhibitor resistance [7]. These in vitro
systems reflect metastatic tumour behaviour and poor
outcome often observed in patients that acquired endo-
crine resistance. For instance, both models display pro-
found morphological and molecular changes, with cells
showing EMT features and invasive/migratory capacity.
EMT has been described as an important mechanism in
tumour metastasis, allowing polarized epithelial cells to
acquire a fibroblast-like phenotype permissive for intra-
vasation and metastasis [24].
Activation of alternative survival signalling pathways
can compensate for ER signalling inhibition following
endocrine therapies [5,6]. Recently, the Notch pathway
has been shown to be a significant factor in the develop-
ment of endocrine resistance [7,8]. It has also been shown
that combining GSI with tamoxifen causes tumour regres-
sion in vivo. Moreover, it has been demonstrated that
Notch signalling is augmented in ETR cells following a
global reprogramming of the epigenome [7]. Here, we
show that ETR cells express high levels of Notch4 and
Nicastrin, a key GS component responsible for the cleav-
age and the subsequent activation of Notch receptors.Importantly, ETR cells express lower levels of Notch1 and
Notch2 compared to the endocrine-sensitive MCF7 cells
suggesting a switch to Notch4 activation after acquiring
endocrine resistance.
Notch receptors have been shown to be important for
the formation of spontaneous mammary tumors in vivo
after overexpression of constitutive, active forms of Notch1
or Notch4 [25]. Moreover, overexpression of constitutively
active Notch4 in normal human mammary epithelial cells
induces transformation in vivo [26].
Notch signalling has also been implicated in EMT where
it modulates the cell-cell adhesion protein E-cadherin [27].
Accordingly, we found low mRNA levels of E-cadherin in
ETR cells. Since protein levels did not significantly change,
we explored E-cadherin cellular localization. We showed a
distrupted E-cadherin at the cell-cell contacts, which was
restored by GSI, anti-Nicastrin mAbs or Notch4 and
Nicastrin siRNA. In addition, several EMT genes were af-
fected after the treatments suggesting a partial EMT
reversal.
We have previously shown that Nicastrin regulates the
EMT process and stem cell content in triple-negative
breast cancers partially through Notch1/Notch4 activa-
tion [13]. Moreover, a critical role of Notch-4 rather
than Notch1 has been recently shown for the survival of
tumour-initiating cells [28].
Increasing evidence suggests that breast CSCs contrib-
ute to endocrine resistance. CSCs may be intrinsically
endocrine resistant because they do not express ERα
while exhibiting high levels of mesenchymal genes [3].
Interestingly, ETR breast cancer cells express high levels
of EGFR and other growth factor receptors that have
been linked to normal breast stem cells [29]. In addition,
it has been demonstrated that Notch receptors are
present in mammary stem cells and progenitor cells, and
are downregulated in differentiated cells [17].
Notch4 appears to be absolutely required for growth
in three-dimensional cultures as the development of
branching structures is completely blocked by anti-Notch4
antibodies or GSI [17] ETR cells expressing increased ex-
pression of growth factor receptors and increased Notch4
levels may reflect an increased proportion of CSCs selected
by endocrine therapies. However, up to the present time
the precise mechanism was unknown.
Here, we demonstrated that TAM-R cells contain a higher
content of CD44+/CD24− CSCs as they form a higher num-
ber of mammospheres in vitro compared to the parental
MCF7 cells. Importantly, pharmacological inhibition of
Notch4 and Nicastrin using GSI PF03084014 and anti-
Nicastrin mAbs is sufficient to decrease the percentage of
CD44+/CD24− cells and the sphere-forming efficiency. These
results suggest that endocrine-resistant tumours are driven
by a stem cell-like population possessing higher levels of
Nicastrin, activated Notch4 and EMT features.
Lombardo et al. Breast Cancer Research 2014, 16:R62 Page 13 of 14
http://breast-cancer-research.com/content/16/3/R62Finally, we demonstrate that Nicastrin overexpression
is sufficient to bypass tamoxifen response and is linked
to acquisition of EMT phenotype. Nicastrin overexpres-
sion induces the EMT process in non-invasive MCF10A
breast cells, partially through Notch1/Notch4 activation
[13]. Moreover, Nicastrin may contribute to drug resist-
ance in human embryonic kidney (HEK293) cells [30].
Therefore it seems likely that Nicastrin overexpression
can overcome endocrine therapy through increased activa-
tion of the Notch pathway. Although Nicastrin overexpres-
sion induced activation of Notch1ICD and Notch3ICD
beside Notch4ICD as a consequence of an increase activity
of gamma secretase [13], we found that Notch4 inhibition
was sufficient to restore tamoxifen sensitivity. This indi-
cates a major role of Notch4 in Nicastrin-mediated resist-
ance to tamoxifen.
Conclusions
In summary, we demonstrated that Nicastrin and Notch4
are key molecules involved in resistance to endocrine ther-
apy. Our data suggest that targeting Notch4 and Nicastrin
is a potential approach to reverse endocrine resistance in
breast cancer patients.
Additional files
Additional file 1: Table S1. Primer list.
Additional file 2: Figure S1. Long-term estrogen-deprived (LTED) cells
are resistant to tamoxifen (4-OH-TAM), phenotypically distinct, more invasive
and migratory compared to wild-type MCF7. (A) MCF7 and LTED cells
treated with vehicle (EtOH) or 10−7 M tamoxifen (4-OH-TAM) were
plated (3 x 103/well) in 96-well plates and allowed to adhere. One plate
was fixed and annotated as Day 0. A sulforhodamine B (SRB) assay was
performed every two days until Day 6. The experiment was repeated
three times and each time six technical replicates were used. (B) Cells
were stained with Crystal Violet and 10X images were taken with
bright-field microscope when cells were 50% confluent (bars represent
400 μm). (C) Boyden chamber-based assay was used to determine the
LTED cells migratory capacity. Cells were allowed migrate for 18 hrs
before the insert was fixed, cut, and mounted in Mowiol infused with
DAPI. 4X images were taken (bars represent 1,000 μm). The results are
representative of two biological and two technical replicates. (D)
Quantification of microRNA (mRNA) levels of epithelial to mesenchymal
transition (EMT) markers or Notch genes (E) analysed by qRT-PCR. Fold
change is shown in LTED compared to MCF7 cells, everything normalised
to GAPDH. (F) Western blot validation for Nicastrin and Notch receptors.
ActinB was used as loading control.
Additional file 3: Figure S2. (A) MCF7 cells were treated with vehicle
(EtOH) or 10−7 M tamoxifen (4-OH-TAM) were plated (3 x 103/well) in 96-
well plates and allowed to adhere. One plate was fixed and annotated as
Day 0. A sulforhodamine B (SRB) assay was performed every two days
until Day 6. The experiment was repeated three times and each time six
technical replicates were used. (B) Western blot analysis of N1ICD, N2ICD,
N3ICD and N4ICD after EDTA treatment in tamoxifen-resistant (TAM-R)
cells. ActinB was used as loading control. (C) Multiple small interfering
RNA (siRNA) for Notch4 was tested. Following knockdown, proteins were
prepared from whole cell lysate and immunoblotted against Notch4.
Quantitation normalised to ActinB is shown.
Additional file 4: Figure S3. Anti-Nicastrin (NCST) monoclonal antibodies
(mAbs) and gamma secretase inhibitors (GSIs) effect on long-term
estrogen-deprived (LTED) and tamoxifen-resistant (TAM-R) cells. (A)Boyden chambers were used to determine cells migratory capacity.
LTED cells were pre-incubated for 30 minutes with 50 μg/ml of mAb1/
2, or 10 μM GSIPF (PF03084014) or GSIRO (RO4929097). Pre-treated cells
were seeded on 6-well plates for 54 hrs, then harvested and counted. A
total of 50,000 were transferred to the chamber upper compartment for
18 hrs before the insert was cut, fixed, rinsed and mounted on Mowiol-DAPI
coverslips. 4X images were taken (bars represent 1,000 μm). The results are
representative of two biological and two technical replicates. (B) RO4929097
has no effect on TAM-R migration activity. Cells were treated as in 2B. 10X
images were taken (bars represent 400 μm) The results are representative of
two biological and two technical replicates. (C, D) Cells were treated as in
2B, microRNA (mRNA) was prepared and transcript levels were determined
relative to GAPDH by qRT-PCR (N = 3 independent experiments, bars
show standard deviation (SD)). EMT and Notch-related genes are
shown. (E) Representative western blot showing GSI RO treatment
followed by NCST increase. Notch4 cleavage is increased (50 KDa) or
unaffected. Total protein was normalised to Actin (N = 3 independent
experiment, bars show SD).
Additional file 5: Figure S4. Representative images showing E-cadherin
localization in tamoxifen-resistant (TAM-R) cells treated with control
immunoglobulin G (IgG), monoclonal antibody 1 (mAb1), monoclonal
antibody 2 (mAb2) and gamma secretase inhibitor Pfizer (GSIPF).
Additional file 6: Figure S5. (A) Pearson correlation coefficient between
RNA-seq data shows that high expression of Notch4 correlate with high
expression of VIM, ZEB1/2 and SNAI1/2/3 while correlating with low
expression of E-cadherin (CHD1). (B) Kaplan-Meier model comparing
post-progression survival in estrogen receptor alpha (ERα)-positive
breast cancer patients showing Notch4 expression.Abbreviations
CSC: cancer stem cells; DCIS: ductal carcinoma in situ; DMEM: Dulbecco’s
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GSI: gamma secretase inhibitor; HER2: human epidermal growth factor 2;
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